The perception of normal human distress has undergone a dramatic transformation over the past three decades. What were previously thought of as everyday anxieties – such as worries about work, finance, relationships, health and the future – have been reclassified as clinical conditions requiring pharmaceutical and state intervention.
This process of medicalisation has been driven by the combination of pharmaceutical industry profit-seeking combined with the expanding definitions of mental illness, resulting in significant impacts on public health systems like the NHS.
Large pharmaceutical companies have played a central role in transforming feelings of worry into Generalised Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD). This shift was not just a scientific advancement, but a cynical marketing strategy designed to expand the market for blockbuster drugs, particularly SSRI antidepressants.
Create the Disease: Marketing campaigns have successfully rebranded everyday anxieties as a diagnosable, biochemical-based medical condition, persuading millions of healthy but worried people that they are suffering from a chronic illness requiring treatment with drugs.
Shaping the Narrative: Pharmaceutical companies have also heavily influenced the psychiatric field, promoting a biomedical narrative that prioritises pharmaceutical treatment over social or psychological wellbeing.
Shifting from Tranquilisers to SSRIs: In the 1990s, the “misery pills” of the past (benzodiazepines) were replaced by SSRIs (such as sertraline, fluoxetine and paroxetine) as the preferred treatment, which were marketed as safer long-term solutions for a wide range of anxiety conditions.
Charities also rely on the narrative of an anxiety epidemic to drive access to increased public funding and philanthropic donations. Fundraising efforts frequently present anxiety as a severe clinical disability, rather than a common emotional response, which can lead politicians and the public to believe that normal negative feelings are signs of a mental illness. Furthermore, charities provide therapy and information services explicitly linked to formal diagnoses, reinforcing the medicalisation model as the primary route to recovery.
In the same way, access to UK benefits, such as personal independence payments (PIP) and universal credit (UC) has become a new primary driver of medicalisation because it requires a clinical label for financial advantage, locking people into a life of drug taking and welfare dependency.
Explosion in Mental Health Claims: As of March 2026, 91% of new sickness benefits claims in the UK since Jan 2022 were recorded as having “mental and behavioural disorders”. This represents a massive increase compared to pre-pandemic levels.
Normal Life as Illness: Many claims now appear to be linked to the normal anxieties of life—such as financial stress or employment problems—rather than a severe, work-disabling condition.
The Benefit/Wage Gap: In some cases, sickness benefits for anxiety pay up to £2,500 more per year than a minimum wage job after tax, creating a financial incentive to remain on welfare rather than returning to work.
Systemic Pressures: The high pressure on the NHS to provide swift solutions for mental health complaints to reduce waiting list times often results in a short consultation and a prescription for antidepressants, cementing the reliance on popping pills rather than addressing the patient’s wider social needs and lack of personal resilience.
Over-prescription: The prevalence of anxiety medication use has risen dramatically, with many patients receiving medication for issues that would not meet the strict definitions of illness.
Depoliticising Distress: By framing everyday worries as a personal medical problem, the welfare system avoids addressing the root causes of anxieties related to social and economic breakdown, which would require difficult, long-term and vote-losing solutions.
The transformation of normal human anxiety into a medical condition has been a hugely successful strategy for the pharmaceutical industry, providing significant profits while expanding the “market” for psychiatric drugs.
This process has not occurred in a vacuum, with the UK welfare system subsequently experiencing an unprecedented rise in claims related to these new, broad definitions of mental illness.
The result is the current complex, often adversarial healthcare/benefits system that struggles to distinguish between serious debilitating levels of anxiety and the normal trials of everyday life, all while the financial costs of both medication and welfare continue to rise way beyond sustainable levels.
A radical and severe dismantling of the Anxiety Money Machine is needed now, and it won’t be quick, easy or pretty.
© Richard Puller 2026
